Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

803.58 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 803.58
Bid (Size) 808.93 (4)
Ask (Size) 811.00 (3)
Prev. Close 803.58
Today's Range 803.58 - 803.58
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties. 
Via Benzinga
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates expected in Q1 2025. 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market

Performance

YTD
+35.69%
+35.69%
1 Month
-3.47%
-3.47%
3 Month
-11.53%
-11.53%
6 Month
-7.10%
-7.10%
1 Year
+37.59%
+37.59%

More News

Read More
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Via The Motley Fool
MarketBeat Week in Review – 12/2 - 12/6
Via MarketBeat
Topics Economy Government Immigration
Exposures Economy Immigration Interest Rates
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Are you living with eczema? It's time to get the care you deserve
Via Brandpoint
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Eli Lilly Stock Price Analysis – Earnings Miss And The Pullback Worth Watching
Via Talk Markets
Topics Earnings Economy Stocks / Equities
Exposures Financial Supply Chain
Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility
Via Benzinga
Alzheimer’s Disease Therapy Provides Patients With Hope
Via Brandpoint
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
Via Investor's Business Daily
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Via MarketBeat
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
Via The Motley Fool
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
Via MarketBeat
Topics Government Lawsuit
Exposures Financial Legal Political
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
Via Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
Lilly Tops Nordisk In Weight Loss Battle
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
Via Benzinga
Eli Lilly Stock Hits 3-Week High, Boosts Retail Mood On Zepbound’s Edge Over Wegovy In Weight-Loss Trial Showdown
Via Stocktwits
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Via Benzinga
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.